Drug intelligence / Profile preview

cyclosporine 2% ophthalmic solution

Development stage
Phase 4
Lead developer
Aravind Eye Care System
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Cyclosporine is a potent immunosuppressive agent that functions as a calcineurin inhibitor. This specific 2% topical ophthalmic formulation is being evaluated by the Aravind Eye Care System for the prevention of corneal graft rejection in patients undergoing penetrating keratoplasty (PKP) or therapeutic keratoplasty (TKP). By binding to intracellular cyclophilin A, cyclosporine forms a complex that inhibits the phosphatase activity of calcineurin. This inhibition blocks the translocation of the nuclear factor of activated T-cells (NFAT) and the subsequent transcription of pro-inflammatory cytokines, most notably interleukin-2 (IL-2). By preventing T-cell activation and proliferation, the drug aims to mitigate the host immune response against donor corneal tissue, particularly in high-risk or therapeutic graft scenarios where standard steroid therapy alone may be insufficient.

Other names
2% cyclosporinecyclosporine 2%topical cyclosporine 2%
02

Targets

CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)PPIF (Cyclophilin D)

Beyond the preview

Go deeper on cyclosporine 2% ophthalmic solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine 2% ophthalmic solution.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call